Tag : LORLATINIB

CONFERENCE UPDATE

First-line lorlatinib continues to show PFS benefit over crizotinib in patients with advanced ALK+ NSCLC: 5-year follow-up of the CROWN study
Lorlatinib is a brain-penetrant third-generation anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitor (TKI) which covers a broader ALK resistance profile than second-generation ALK TKIs. It has previously demonstrated improved PFS and IC activity compared to crizotinib in treatment-naïve patients with advanced ALK+ NSCLC in the ongoing randomized phase 3 CROWN study.
First-line lorlatinib shows 5-year benefits in Asian patients with ALK+ NSCLC: Post-hoc analysis from the CROWN trial
Lorlatinib, a third-generation, brain-penetrant anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitor, demonstrates potent antitumor activity in patients with ALK-positive (ALK+) non-small cell lung carcinoma (NSCLC) and is approved as a first-line treatment in many countries. This post-hoc analysis presents long-term outcomes in the Asian subgroup of the CROWN study, following a 5-year observation period.